Market Currents
Shares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its...
-
Thursday, August 30, 2012, 2:40 PM ETShares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its bottom line earlier today. Net earnings rose 25% Y/Y, as the clinical-testing company's streak of double-digit revenue growth continued, but investors appear to be taking advantage of near 52-week highs to lock in profits as sales growth shows signs of stagnating.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 1 comment:
But sales were up 16.4%! So, maybe it was a
miss by the analysts' sales estimates or patients
decided to take long weekends and go to the beach.
I didn't see any big upside surprises in revenues
being issued by competitors.